{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:36:42Z","timestamp":1787063802520,"version":"build-2736575974"},"reference-count":107,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T00:00:00Z","timestamp":1556323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MH CZ - DRO UHHK","award":["00179906"],"award-info":[{"award-number":["00179906"]}]},{"name":"Charles University research projects","award":["PROGRES Q40-15, PROGRES Q47"],"award-info":[{"award-number":["PROGRES Q40-15, PROGRES Q47"]}]},{"name":"EFSA-CDN","award":["[No. CZ.02.1.01\/0.0\/0.0\/16_019\/0000841] co-funded by ERDF"],"award-info":[{"award-number":["[No. CZ.02.1.01\/0.0\/0.0\/16_019\/0000841] co-funded by ERDF"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related chronic inflammatory diseases. Glucocorticoids (GCs) are first-choice drugs for PMR and GCA, although some patients show poor responsiveness to the initial GC regimen or experience flares after GC tapering. To date, no valid biomarkers have been found to predict which patients are at most risk for developing GC resistance. In this review, we summarize PMR- and GCA-related gene polymorphisms and we associate these gene variants with GC resistance and therapeutic outcomes. A limited number of GC resistance associated-polymorphisms have been published so far, mostly related to HLA-DRB1*04 allele. Other genes such ICAM-1, TLR4 and 9, VEGF, and INFG may play a role, although discrepancies are often found among different populations. We conclude that more studies are required to identify reliable biomarkers of GC resistance. Such biomarkers could help distinguish non-responders from responders to GC treatment, with concomitant consequences for therapeutic strategy.<\/jats:p>","DOI":"10.3390\/jcm8050582","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T02:57:32Z","timestamp":1556506652000},"page":"582","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis"],"prefix":"10.3390","volume":"8","author":[{"given":"Tomas","family":"Smutny","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Centre for Drug Development, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Barvik","sequence":"additional","affiliation":[{"name":"Institute of Physics, Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Veleta","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University Hospital in Hradec Kralove,  500 05 Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Pavek","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Centre for Drug Development, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Soukup","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, 2nd Department of Internal Medicine\u2013Gastroenterology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcgg.2010.12.001","article-title":"Polymyalgia rheumatica and giant cell arteritis","volume":"2","author":"Patel","year":"2011","journal-title":"J. Clin. Gerontol. Geriatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0036933014551115","article-title":"Polymyalgia rheumatica: 125 years of epidemiological progress?","volume":"60","author":"Rooney","year":"2015","journal-title":"Scott. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nesher, G., and Breuer, G.S. (2016). Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update. Rambam. Maimonides Med. J., 7.","DOI":"10.5041\/RMMJ.10262"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","article-title":"Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: A prospective study in 35 patients","volume":"46","author":"Blockmans","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/ard.2003.011692","article-title":"Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: A quantitative PET study","volume":"63","author":"Moosig","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.semarthrit.2003.09.008","article-title":"Are polymyalgia rheumatica and giant cell arteritis the same disease?","volume":"33","author":"Cantini","year":"2004","journal-title":"Semin. Arthritis. Rheum."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Matteson","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/sarh.2002.50025","article-title":"Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica","volume":"33","author":"Amoli","year":"2003","journal-title":"Semin. Arthritis. Rheum."},{"key":"ref_9","first-page":"1461","article-title":"Giant cell arteritis, polymyalgia rheumatica and Takayasu\u2019s arteritis","volume":"Volume 2","author":"Firestein","year":"2013","journal-title":"Kelley\u2019s Textbook of Rheumatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1442-9071.2006.01186.x","article-title":"Giant cell arteritis","volume":"34","author":"Carroll","year":"2006","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","article-title":"Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: Angiogenic activity of interleukin-6 as a potential protective mechanism","volume":"107","author":"Segarra","year":"2003","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis. Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.2008.103663","article-title":"Circulating cytokines in active polymyalgia rheumatica","volume":"69","author":"Mata","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","article-title":"Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis","volume":"121","author":"Weyand","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","article-title":"Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: A prospective followup study","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis. Rheum."},{"key":"ref_18","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica","volume":"32","author":"Kremers","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.23924","article-title":"Serum interleukin-6 receptor in polymyalgia rheumatica: A potential marker of relapse\/recurrence risk","volume":"59","author":"Pulsatelli","year":"2008","journal-title":"Arthritis. Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archinte.159.6.577","article-title":"Corticosteroid requirements in polymyalgia rheumatica","volume":"159","author":"Weyand","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","article-title":"Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR)","volume":"33","author":"Lee","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_22","first-page":"1945","article-title":"Longterm therapy in polymyalgia rheumatica: Effect of coexistent temporal arteritis","volume":"26","author":"Narvaez","year":"1999","journal-title":"J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF02208345","article-title":"The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica","volume":"14","author":"Schreiber","year":"1995","journal-title":"Clin. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2000.8366","article-title":"Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study","volume":"30","author":"Cantini","year":"2000","journal-title":"Semin. Arthritis. Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.42.4.374","article-title":"Polymyalgia rheumatica and corticosteroids: How much for how long?","volume":"42","author":"Behn","year":"1983","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0002-9343(85)90309-2","article-title":"Polymyalgia rheumatica. Duration of therapy and long-term outcome","volume":"79","author":"Ayoub","year":"1985","journal-title":"Am. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/ard.52.12.847","article-title":"The clinical and laboratory course of polymyalgia rheumatica\/giant cell arteritis after the first two months of treatment","volume":"52","author":"Kyle","year":"1993","journal-title":"Ann. Rheum Dis"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cimmino, M.A., Parodi, M., Montecucco, C., and Caporali, R. (2011). The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet. Disord., 12.","DOI":"10.1186\/1471-2474-12-94"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e3524","DOI":"10.1097\/MD.0000000000003524","article-title":"Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study","volume":"95","author":"Restuccia","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: Prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1677\/joe.0.1780339","article-title":"Glucocorticoid resistance in inflammatory bowel disease","volume":"178","author":"Farrell","year":"2003","journal-title":"J. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archinternmed.2007.41","article-title":"Glucocorticoid receptor gene and risk of cardiovascular disease","volume":"168","author":"Koper","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1749-6632.2009.05013.x","article-title":"Clinical features associated with glucocorticoid receptor polymorphisms. An overview","volume":"1179","author":"Manenschijn","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3748\/wjg.v17.i9.1095","article-title":"Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease","volume":"17","author":"Franca","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/1744666X.2018.1468251","article-title":"Tocilizumab for the treatment of giant cell arteritis","volume":"14","author":"Schirmer","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrendo.2013.183","article-title":"Glucocorticoid sensitivity in health and disease","volume":"9","author":"Quax","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_38","first-page":"294","article-title":"Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis","volume":"43","author":"Segarra","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3899\/jrheum.090075","article-title":"Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica","volume":"36","author":"Braun","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"D833","DOI":"10.1093\/nar\/gkw943","article-title":"DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants","volume":"45","author":"Pinero","year":"2017","journal-title":"Nucleic. Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.57.6.380","article-title":"Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis","volume":"57","author":"Rauzy","year":"1998","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","first-page":"2140","article-title":"Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association","volume":"25","author":"Dababneh","year":"1998","journal-title":"J. Rheumatol."},{"key":"ref_43","first-page":"94","article-title":"Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population","volume":"25","author":"Combe","year":"1998","journal-title":"J. Rheumatol."},{"key":"ref_44","first-page":"2395","article-title":"HLA-DRB1, DQA1, and DQB1 alleles associated with giant cell arteritis in northern Italy","volume":"26","author":"Salvarani","year":"1999","journal-title":"J. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.semarthrit.2003.12.001","article-title":"HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: Influence on clinical subgroups and prognosis","volume":"34","author":"Bartolome","year":"2004","journal-title":"Semin. Arthritis. Rheum."},{"key":"ref_46","first-page":"2148","article-title":"Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis","volume":"29","author":"Jacobsen","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_47","first-page":"S12","article-title":"Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis","volume":"29","author":"Castaneda","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_48","first-page":"1510","article-title":"Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis","volume":"32","author":"Oliver","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_49","first-page":"1600","article-title":"Lack of association between intercellular adhesion molecule-1 gene polymorphisms and giant cell arteritis","volume":"28","author":"Amoli","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_50","first-page":"285","article-title":"Lack of association of a functional -94ins\/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in northwest Spain","volume":"33","author":"Martin","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_51","first-page":"2173","article-title":"Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis","volume":"32","author":"Salvarani","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_52","first-page":"179","article-title":"IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis","volume":"20","author":"Hajeer","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_53","first-page":"31","article-title":"Lack of association between IFNGR1 gene polymorphisms and biopsy-proven giant cell arteritis","volume":"28","author":"Torres","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_54","first-page":"S18","article-title":"Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica","volume":"22","author":"Hajeer","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_55","first-page":"1737","article-title":"A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis","volume":"32","author":"Rueda","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.humimm.2008.10.011","article-title":"Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: Association of IL-1RN*2\/2 genotype with polymyalgia rheumatica","volume":"70","author":"Mata","year":"2009","journal-title":"Hum. Immunol."},{"key":"ref_57","first-page":"507","article-title":"MCP-1 gene haplotype association in biopsy proven giant cell arteritis","volume":"32","author":"Amoli","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_58","first-page":"1535","article-title":"Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in Northwestern Spain","volume":"34","author":"Rueda","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1002\/art.22218","article-title":"Interleukin-10 promoter polymorphisms in giant cell arteritis","volume":"54","author":"Boiardi","year":"2006","journal-title":"Arthritis. Rheum."},{"key":"ref_60","first-page":"850","article-title":"Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis","volume":"35","author":"Rueda","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_61","first-page":"S40","article-title":"Toll-like receptor 4 (TLR4) gene polymorphisms in giant cell arteritis","volume":"27","author":"Boiardi","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3899\/jrheum.081286","article-title":"Association between toll-like receptor 4 gene polymorphism and biopsy-proven giant cell arteritis","volume":"36","author":"Torres","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/rheumatology\/ker168","article-title":"Lack of association between Toll-like receptor 4 gene polymorphisms and giant cell arteritis","volume":"50","author":"Beares","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/03009742.2012.704392","article-title":"Toll-like receptor 9 gene polymorphisms in polymyalgia rheumatica and giant cell arteritis","volume":"41","author":"Beares","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1002\/art.22922","article-title":"PlA1\/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis","volume":"56","author":"Salvarani","year":"2007","journal-title":"Arthritis. Rheum."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/ard.58.5.303","article-title":"HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: Correlation with disease severity","volume":"58","author":"Salvarani","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"ref_67","first-page":"703","article-title":"Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse\/recurrence in polymyalgia rheumatica","volume":"33","author":"Boiardi","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_68","first-page":"795","article-title":"Toll-like receptor 4 gene polymorphisms in polymyalgia rheumatica and elderly-onset rheumatoid arthritis","volume":"29","author":"Beares","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_69","first-page":"591","article-title":"Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica","volume":"18","author":"Salvarani","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_70","first-page":"675","article-title":"Interleukin-1 cluster and tumor necrosis factor-alpha gene polymorphisms in polymyalgia rheumatica","volume":"18","author":"Boiardi","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_71","first-page":"502","article-title":"Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica","volume":"29","author":"Amoli","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_72","first-page":"1215","article-title":"Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica\/giant cell arteritis: Association with disease risk and severity","volume":"27","author":"Salvarani","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_73","first-page":"484","article-title":"Influence of interleukin 10 promoter polymorphisms in polymyalgia rheumatica: Disease susceptibility and functional consequences","volume":"32","author":"Tripathi","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_74","first-page":"726","article-title":"T-786C single nucleotide polymorphism of the endothelial nitric oxide synthase gene as a risk factor for endothelial dysfunction in polymyalgia rheumatica","volume":"33","author":"Loffers","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_75","first-page":"122","article-title":"Seronegative rheumatoid arthritis in elderly and polymyalgia rheumatica have similar patterns of HLA association","volume":"28","author":"Hajeer","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br. J. Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/rheumatology\/kel128","article-title":"Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis","volume":"45","author":"Cid","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"ref_79","first-page":"133","article-title":"Corticotropin releasing hormone promoter polymorphisms in giant cell arteritis and polymyalgia rheumatica","volume":"20","author":"Hajeer","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1136\/annrheumdis-2013-203641","article-title":"Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis","volume":"72","author":"Serrano","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/1529-0131(200011)43:11<2472::AID-ANR14>3.0.CO;2-B","article-title":"Vascular endothelial growth factor production in polymyalgia rheumatica","volume":"43","author":"Meliconi","year":"2000","journal-title":"Arthritis. Rheum."},{"key":"ref_82","first-page":"2160","article-title":"Vascular endothelial growth factor gene polymorphisms in giant cell arteritis","volume":"30","author":"Boiardi","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/1744666X.2016.1089173","article-title":"New insights into the pathogenesis of giant cell arteritis and hopes for the clinic","volume":"12","author":"Carmona","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1136\/annrheumdis-2014-205261","article-title":"Influence of the IL17A locus in giant cell arteritis susceptibility","volume":"73","author":"Marquez","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/annrheumdis-2012-201836","article-title":"Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis","volume":"72","author":"Lozano","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","article-title":"Immune mechanisms in medium and large-vessel vasculitis","volume":"9","author":"Weyand","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/rheumatology\/kev102","article-title":"Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis","volume":"54","author":"Ciccia","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3899\/jrheum.110685","article-title":"A nonsynonymous functional variant of the ITGAM gene is not involved in biopsy-proven giant cell arteritis","volume":"38","author":"Carmona","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3899\/jrheum.081060","article-title":"Lack of association between STAT4 gene polymorphism and biopsy-proven giant cell arteritis","volume":"36","author":"Morado","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3899\/jrheum.100388","article-title":"Influence of IL2RA rs2104286 polymorphism in the risk of biopsy-proven giant cell arteritis","volume":"37","author":"Castaneda","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3899\/jrheum.091142","article-title":"Lack of association between the rs6920220 (G\/A) polymorphism of the 6q23 region and biopsy-proven giant cell arteritis","volume":"37","author":"Torres","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3899\/jrheum.090646","article-title":"Lack of association between TRAF1\/C5 gene polymorphisms and biopsy-proven giant cell arteritis","volume":"37","author":"Torres","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3899\/jrheum.120038","article-title":"Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis","volume":"39","author":"Carmona","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3899\/jrheum.101046","article-title":"Role of rs1343151 IL23R and rs3790567 IL12RB2 polymorphisms in biopsy-proven giant cell arteritis","volume":"38","author":"Carmona","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_96","first-page":"S29","article-title":"Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population","volume":"30","author":"Serrano","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/ard.2007.074666","article-title":"-463 G\/A myeloperoxidase promoter polymorphism in giant cell arteritis","volume":"67","author":"Salvarani","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3899\/jrheum.080707","article-title":"C-reactive protein gene polymorphisms in biopsy-proven giant cell arteritis from Northwestern Spain","volume":"36","author":"Martin","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_99","first-page":"S5","article-title":"A case-control study suggests that the CCR6 locus is not involved in the susceptibility to giant cell arteritis","volume":"31","author":"Serrano","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3899\/jrheum.090744","article-title":"Lack of association between IRF5 gene polymorphisms and biopsy-proven giant cell arteritis","volume":"37","author":"Torres","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3899\/jrheum.100016","article-title":"Role of BANK1 gene polymorphisms in biopsy-proven giant cell arteritis","volume":"37","author":"Torres","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/art.11307","article-title":"Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis","volume":"48","author":"Salvarani","year":"2003","journal-title":"Arthritis. Rheum."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3899\/jrheum.100362","article-title":"Influence of CD40 rs1883832 polymorphism in susceptibility to and clinical manifestations of biopsy-proven giant cell arteritis","volume":"37","author":"Castaneda","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.humimm.2010.02.016","article-title":"Role of the C8orf13-BLK region in biopsy-proven giant cell arteritis","volume":"71","author":"Torres","year":"2010","journal-title":"Hum. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_106","first-page":"E970","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/art.39037","article-title":"Th1 and Th17 cytokines drive inflammation in Takayasu arteritis","volume":"67","author":"Saadoun","year":"2015","journal-title":"Arthritis. Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/5\/582\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:47:37Z","timestamp":1760186857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/5\/582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,27]]},"references-count":107,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["jcm8050582"],"URL":"https:\/\/doi.org\/10.3390\/jcm8050582","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,27]]}}}